Work

Intensive treatment of acute leukemia in adults 70 years of age and older

Year: 1987

Type: article

Abstract: The results of treatment for acute leukemia since 1973 in 87 patients aged 70 years or more are summarized. The overall complete remission rate was 27/78 (35%) in acute myelogenous leukemia and 5/9 (56%) in acute lymphocytic leukemia or acute undifferentiated leukemia for cytosine arabinoside combined with either anthracyclines (rubidazone or Adriamycin [doxorubicin]) or m-AMSA (amsacrine). The remission duration was short with a median of 33 weeks, and the median overall survival was only 6 weeks. Those patients without identifiable infection, liver enlargement, and a serum glutamic oxaloacetic transaminase less than or equal to 40 U/ml constituted a more favorable subgroup. Although the complete remission rate improved further research is needed to develop effective maintenance strategies.

Source: Cancer

DOI: 10.1002/1097-0142(19870715)60:2<149::aid-cncr2820600204>3.0.co;2-f

Authors: Ronald S. Walters, Hagop M. Kantarjian, Michael J. Keating, Elihu H. Estey, Kenneth B. McCredie, Emil J. Freireich

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Cancer Institute